Enveric Biosciences, Inc.ENVB
Price (close)
$1.54
Market cap
$6.1M
P/E
—
Revenue (TTM)
—
Net income
-$8.7M
Dividend yield
—
1-year total return
-78.9%
Net margin
—
Revenue growth
—
Debt / equity
—
What Enveric Biosciences, Inc. does.
the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell company immediately prior
to the completion of a “reverse merger” transaction on May 26, 2015, whereby Ameri100 Acquisition, Inc., a Delaware corporation
and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc. (“Ameri and Partners”), a Delaware
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$6.9M | -$49.0M | -$18.5M | -$17.3M | -$9.6M | -$8.8M |
| Free cash flow | — | -$11.6M | -$17.7M | -$14.1M | — | — |
More on ENVB.
- Enveric Biosciences, Inc. summary
- Enveric Biosciences, Inc. financial statements
- Enveric Biosciences, Inc. key metrics
- Enveric Biosciences, Inc. health scores and style box
- Enveric Biosciences, Inc. earnings
- Enveric Biosciences, Inc. dividends
- Enveric Biosciences, Inc. valuation
- Enveric Biosciences, Inc. ownership and insiders
- Enveric Biosciences, Inc. peers
Figures from Enveric Biosciences, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.